Business Wire

MITSUBISHI-HITACHI

19.5.2020 14:02:16 CEST | Business Wire | Press release

Share
MHPS Captures Global Gas Turbine Market Share Leadership Again

Mitsubishi Hitachi Power Systems (MHPS) ranks first in market share by megawatts for gas turbine orders in 2020 according to data obtained from McCoy Power Reports. First quarter global orders of 2,638 MW brought MHPS’ market share to 28.5 percent globally. This increase in gas turbine market share was largely responsible for worldwide order booking increasing 19.7 percent during MHPS’ fiscal year ending March 31, 2020.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200519005485/en/

“The extremely competitive global gas turbine market has moved in our direction with a clear preference for our JAC gas turbines, which are more reliable than competitor’s gas turbines while providing record-setting fuel efficiency and output,” said Ken Kawai, MHPS President and Chief Executive Officer. “Sales of MHPS’ gas turbines in both the advanced class and aero-derivative segments have gained momentum as utilities, independent power producers and municipalities around the world seek to lower their electricity cost through our unique combination of proven reliability and world class performance.”

MHPS’ J-Series gas turbines first entered commercial operation in 2011 and hold world-record reliability at 99.5%. In addition, they deliver combined cycle efficiency greater than 64%. The installed fleet of J-Series gas turbines recently achieved one million hours of commercial operation worldwide, which is nearly double that of competitors’ similar sized gas turbines.

Boosting MHPS’ first quarter 2020 market share was an order for the first two renewable-hydrogen-capable JAC gas turbines for the Intermountain Power Agency in Delta, Utah. Dan Eldredge of the Intermountain Power Agency said, "We chose MHPS' JAC power trains because they offered the best overall solution for our power generation equipment requirements, including the fuel flexibility that will enable us to meet our incremental goals toward 100% carbon-free power generation by 2045. With MHPS' tools and support, we expect to reliably provide cleaner power for decades to come."

Forty-five J-Series gas turbines are in commercial operation, and total ordered capacity exceeds 25 GW globally. One hundred and four units have been technically selected in Brazil, Canada, Japan, Mexico, Peru, South Korea, Taiwan, Thailand, and the United States.

“The marketplace has recognized our efforts through a wave of technical selections and orders placed,” said Junichiro Masada, Senior Vice President, Co-Chief Technology Officer, and Deputy Head of Turbomachinery Headquarters, MHPS. “And we continue to improve our technology. For example, we recently synced to the grid in Takasago, Japan, and reached full load with the latest 60 Hz enhancement of the JAC, demonstrating record-setting output and combined cycle efficiency. Competitors are years away from entering operation with a gas turbine of this size or efficiency. In addition, we recently demonstrated a significant performance enhancement of the FT4000 at our test facility in West Palm Beach, Florida.”

The FT4000 aero-derivative gas turbine, with multiple active projects in North America and internationally, has tripled its global footprint in the past two years and captured significant market share in its class since the purchase of PW Power Systems (PWPS) in 2013. The PWPS FT4000 first entered commercial operation in 2015 and delivers industry-leading simple cycle efficiency, start time and ramp rate.

“We are proud that our technology has launched us to global leadership in the competitive gas turbine market,” said Ken Kawai, President and Chief Executive Officer. “We value the contributions of our employees around the world who are focused on bringing advanced technologies and energy solutions to the marketplace for affordable and reliable power supplies. We remain committed to enabling a decarbonized economy and helping to resolve the challenges facing our global society.”

About Mitsubishi Hitachi Power Systems, Ltd.

Mitsubishi Hitachi Power Systems, Ltd. (MHPS), headquartered in Yokohama, Japan, is a joint venture formed in February 2014 by Mitsubishi Heavy Industries, Ltd. and Hitachi, Ltd. integrating their operations in thermal power generation systems and other related businesses. MHPS recently announced that its name will soon change to Mitsubishi Power. MHPS today ranks among the world’s leading suppliers of equipment and services to the power generation market, backed by 100 billion yen in capital and approximately 20,000 employees worldwide. The Company’s products include GTCC (gas turbine combined-cycle) and IGCC (integrated coal gasification combined-cycle) power plants, gas/coal/oil-fired (steam) power plants, boilers, generators, gas and steam turbines, geothermal power plants, AQCS (air quality control systems), power plant peripheral equipment and solid-oxide fuel cells (SOFC). For more information, please visit the Company's website at https://www.mhps.com .

Follow us at
https://twitter.com/MHPS_Global , or http://www.linkedin.com/showcase/mhps

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release

The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t

Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye